NC-R17

• UNSPSC Description:

  NC-R17 is a PROTAC-class, non-covalent GPX4 degrader based on RSL3, involved in ferroptosis. NC-R17 has antitumor activity and is used for non-covalent GPX4 PROTAC design[1]. NC-R17 consists of a target protein ligand (red part) Demethyl-RSL3 (HY-135832); an E3 ubiquitin ligase ligand (blue part) Lenalidomide (HY-A0003) and a PROTAC linker (black part) (HY-169376). E3 ubiquitin ligase and linker can form Lenalidomide-C13-piperazine-Boc (HY-169377)[1][2].

• Target Antigen:

  Ferroptosis; Glutathione Peroxidase; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Metabolic Enzyme/Protease;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nc-r17.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(OC)[C@@H]1N(C(CC)=O)[C@@H](C2=CC=C(C(N3CCN(CCCCCCCCCCCCCNC4=C(CN(C5C(NC(CC5)=O)=O)C6=O)C6=CC=C4)CC3)=O)C=C2)C7=C(C(C=CC=C8)=C8N7)C1

• Molecular Weight:

  914.14

• References & Citations:

  [1]Zheng C, et al. Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization. Eur J Med Chem. 2023 Jul 5;255:115393.|[2]Luo Y, et al. Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches. Drug Des Devel Ther. 2024 Jun 21;18:2485-2529.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3049087-34-2